VCYT
VERACYTE, INC.
Key Financials
Net Income
$66.4M
↑ 174.9%
Gross Profit
$362.5M
↑ 21.6%
Revenue
$517.1M
↑ 16.0%
Operating Income
$57.8M
↑ 257.9%
Total Assets
$1.4B
↑ 8.2%
Total Liabilities
$96.4M
↓ 22.3%
Cash & Equivalents
$362.6M
↑ 51.7%
Shareholders' Equity
$1.3B
↑ 11.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 5/13/2026 | View on SEC |
| SCHEDULE 13G | 5/12/2026 | View on SEC |
| 4 | 5/8/2026 | View on SEC |
| 144 | 5/6/2026 | View on SEC |
| SCHEDULE 13G/A | 5/6/2026 | View on SEC |
| 10-Q | 5/6/2026 | View on SEC |
| 8-K | 5/5/2026 | View on SEC |
| SCHEDULE 13G | 4/30/2026 | View on SEC |
| SCHEDULE 13G | 4/29/2026 | View on SEC |
| ARS | 4/22/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | VCYT |
| Company Name | VERACYTE, INC. |
| CIK | 1384101 |
| Sector | Services-Medical Laboratories |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 8071 |
| SIC Description | Services-Medical Laboratories |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (650) 243-6300 |